Episodes

  • 5-Minute Journal Club Issue 8 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

    5-Minute Journal Club Issue 8 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
    May 28 2025

    Dr Rinath Jeselsohn from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer.

    CME information and select publications here.

    Show More Show Less
    14 mins
  • 5-Minute Journal Club Issue 7 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

    5-Minute Journal Club Issue 7 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
    May 19 2025

    Dr Rinath M Jeselsohn from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer.

    CME information and select publications here.

    Show More Show Less
    18 mins
  • Breast Cancer — Year in Review Series on Relevant New Datasets and Advances

    Breast Cancer — Year in Review Series on Relevant New Datasets and Advances
    May 6 2025

    Dr Rebecca Dent from National Cancer Centre Singapore and Dr Nancy Lin from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss important efficacy and safety data from 2024 related to the management of localized and advanced breast cancers.

    CME information and select publications here.
    Show More Show Less
    1 hr
  • Oncology Nursing Edition: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress

    Oncology Nursing Edition: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress
    Apr 26 2025

    Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events.

    NCPD information and select publications here.

    Show More Show Less
    1 hr and 33 mins
  • Hormone Receptor-Positive Metastatic Breast Cancer — An Interview with Dr Adam M Brufsky on the Impact of Biomarkers and Existing Comorbidities on the Selection of First-Line Therapy

    Hormone Receptor-Positive Metastatic Breast Cancer — An Interview with Dr Adam M Brufsky on the Impact of Biomarkers and Existing Comorbidities on the Selection of First-Line Therapy
    Apr 25 2025

    Dr Adam M Brufsky from the University of Pittsburgh discusses first-line treatment selection for patients with HR-positive metastatic breast cancer and preexisting medical conditions.

    CME information and select publications here.

    Show More Show Less
    53 mins
  • HER2-Positive and Triple-Negative Breast Cancer — Fourth Annual National General Medical Oncology Summit

    HER2-Positive and Triple-Negative Breast Cancer — Fourth Annual National General Medical Oncology Summit
    Apr 21 2025

    Clinical investigators discuss available data guiding the management of HER2-positive, triple-negative and localized breast cancer. 

    CME information and select publications here.
    Show More Show Less
    1 hr and 40 mins
  • HR-Positive Breast Cancer — Fourth Annual National General Medical Oncology Summit

    HR-Positive Breast Cancer — Fourth Annual National General Medical Oncology Summit
    Apr 13 2025

    Clinical investigators discuss available data guiding the management of hormone receptor-positive metastatic breast cancer.

    CME information and select publications here.
    Show More Show Less
    1 hr and 59 mins
  • Breast Cancer — An Interview with Dr Adrienne G Waks on Recent Trial Updates

    Breast Cancer — An Interview with Dr Adrienne G Waks on Recent Trial Updates
    Apr 8 2025

    Dr Adrienne G Waks from Dana-Farber Cancer Institute in Boston, Massachusetts, reviews recent trial updates and their significance for the management of breast cancer.

    CME information and select publications here.
    Show More Show Less
    55 mins